PWM
PTCT icon

Parkworth Wealth Management’s PTC Therapeutics PTCT Stock Holding History

Parkworth Wealth Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$98 Hold
2
– – ﹤0.01% 1137
2025
Q1 		$102 Hold
2
– – ﹤0.01% 932
2024
Q4 		$90 Buy
+2
New +$86 ﹤0.01% 1013

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parkworth Wealth Management's PTCT Position: Q2 2025 in Review

Parkworth Wealth Management held its PTC Therapeutics (PTCT) position steady in Q2 2025 at 2 shares worth $98. The position accounts for ﹤0.01% of the portfolio, ranked #1137.

Parkworth Wealth Management first reported a position in PTCT in Q4 2024 and has held it in 3 quarters since. The position peaked at $102 in Q1 2025. 283 funds tracked by Wall St. Rank hold PTCT as of Q2 2025.

  • Parkworth Wealth Management held 2 shares of PTC Therapeutics worth $98 as of Q2 2025.
  • Parkworth Wealth Management left its PTC Therapeutics share count unchanged in Q2 2025.
  • PTC Therapeutics made up ﹤0.01% of Parkworth Wealth Management's portfolio in Q2 2025, its #1137 holding.
  • Parkworth Wealth Management first reported a position in PTC Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • Parkworth Wealth Management's PTC Therapeutics position peaked at $102 in Q1 2025.
  • 283 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2025.

Based on Parkworth Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.